Clinical Utility of FoundationOne Tissue Molecular Profiling in Men with Metastatic Prostate Cancer

PURPOSE: Targeted inhibitors and immunotherapy have entered the treatment landscape of metastatic prostate cancer. Genomic testing may uncover which patients benefit most from these therapies. We report the clinical utility and benefits of FoundationOne testing in men with advanced prostate cancer....

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Urol Oncol
Päätekijät: Zhu, Jason, Tucker, Matthew, Marin, Daniele, Gupta, Rajan T., Healy, Patrick, Humeniuk, Michael, Jarvis, Casey, Zhang, Tian, McNamara, Megan, George, Daniel J., Wu, Yuan, Lisi, Stacey, Armstrong, Andrew J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2019
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6823135/
https://ncbi.nlm.nih.gov/pubmed/31327751
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2019.06.015
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia